BlackRock’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

BlackRock’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-253	Closed	-$5.7K	–	5639
2023 Q2	$5.7K	Sell	253 -80,452	-100%	-$584K	﹤0.01%	5299
2023 Q1	$976K	Sell	80,705 -1,007	-1%	-$10.5K	﹤0.01%	4344
2022 Q4	$372K	Buy	81,712 +83	+0.1%	+$474	﹤0.01%	4689
2022 Q3	$535K	Sell	81,629 -378	-0.5%	-$3.45K	﹤0.01%	4709
2022 Q2	$885K	Sell	82,007 -49,821	-38%	-$670K	﹤0.01%	4586
2022 Q1	$2.52M	Sell	131,828 -1,753	-1%	-$39.1K	﹤0.01%	4294
2021 Q4	$4.79M	Sell	133,581 -338	-0.3%	-$19.2K	﹤0.01%	4009
2021 Q3	$9.84M	Buy	133,919 +25,897	+24%	+$1.99M	﹤0.01%	3678
2021 Q2	$15.1M	Buy	108,022 +9,188	+9%	+$1.61M	﹤0.01%	3462
2021 Q1	$28.7M	Buy	98,834 +13,304	+16%	+$5.29M	﹤0.01%	2974
2020 Q4	$53.4M	Buy	+85,530	New	+$38.8M	﹤0.01%	2428

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BlackRock's SGTX Position: Q3 2023 in Review

BlackRock sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 253 shares — an estimated $5.7K sold.

BlackRock first reported a position in SGTX in Q4 2020 and held it in 11 quarters. The position peaked at $53.4M in Q4 2020. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

BlackRock reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 253 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $5.7K.
BlackRock first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
BlackRock's Sigilon Therapeutics, Inc. Common Stock position peaked at $53.4M in Q4 2020.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.